Encodia

About Encodia

The startup develops protein analysis software that utilizes reverse-translation technology to convert peptide sequences into DNA, enabling single-molecule protein sequencing. This platform provides researchers with complete proteome information at scale, facilitating more efficient protein sample analysis.

```xml <problem> Current proteomic research is limited by difficulties in scaling studies, hindering the comprehensive analysis of proteins needed to understand complex biological processes and diseases. Traditional methods lack the throughput and scale of modern genomics, impeding advancements in personalized medicine and multiomic research. </problem> <solution> Encodia's ProteoCode™ technology addresses this limitation by reverse-translating peptide sequences into DNA libraries, enabling protein sequencing at a scale comparable to next-generation sequencing (NGS). This approach uses affinity reagent binders with DNA barcode tags to identify amino acids within peptides, creating a library of billions of elements for in-depth protein analysis. The resulting data integrates with multiomic approaches, providing researchers with comprehensive insights into cellular processes and accelerating discoveries in human health. By scaling proteomic studies, Encodia facilitates a deeper understanding of biology and enables personalized medicine approaches. </solution> <features> - Reverse-translation of peptide sequences into DNA libraries for high-throughput protein sequencing. - Compatibility with next-generation sequencing (NGS) platforms for scalable analysis. - Affinity reagent binders with DNA barcode tags for amino acid identification. - Ability to create billions of library elements, each identifying an amino acid in the peptide. - Integration with multiomic data analysis pipelines. </features> <target_audience> The primary target audience includes researchers and scientists in the fields of proteomics, genomics, personalized medicine, and multiomics, as well as pharmaceutical and biotechnology companies. </target_audience> ```

What does Encodia do?

The startup develops protein analysis software that utilizes reverse-translation technology to convert peptide sequences into DNA, enabling single-molecule protein sequencing. This platform provides researchers with complete proteome information at scale, facilitating more efficient protein sample analysis.

Where is Encodia located?

Encodia is based in San Diego, United States.

When was Encodia founded?

Encodia was founded in 2015.

How much funding has Encodia raised?

Encodia has raised 168990000.

Location
San Diego, United States
Founded
2015
Funding
168990000
Employees
54 employees
Major Investors
Northpond Ventures, Deerfield

Find Investable Startups and Competitors

Search thousands of startups using natural language

Encodia

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

The startup develops protein analysis software that utilizes reverse-translation technology to convert peptide sequences into DNA, enabling single-molecule protein sequencing. This platform provides researchers with complete proteome information at scale, facilitating more efficient protein sample analysis.

encodia.com7K+
cb
Crunchbase
Founded 2015San Diego, United States

Funding

$

Estimated Funding

$100M+

Major Investors

Northpond Ventures, Deerfield

Team (50+)

No team information available.

Company Description

Problem

Current proteomic research is limited by difficulties in scaling studies, hindering the comprehensive analysis of proteins needed to understand complex biological processes and diseases. Traditional methods lack the throughput and scale of modern genomics, impeding advancements in personalized medicine and multiomic research.

Solution

Encodia's ProteoCode™ technology addresses this limitation by reverse-translating peptide sequences into DNA libraries, enabling protein sequencing at a scale comparable to next-generation sequencing (NGS). This approach uses affinity reagent binders with DNA barcode tags to identify amino acids within peptides, creating a library of billions of elements for in-depth protein analysis. The resulting data integrates with multiomic approaches, providing researchers with comprehensive insights into cellular processes and accelerating discoveries in human health. By scaling proteomic studies, Encodia facilitates a deeper understanding of biology and enables personalized medicine approaches.

Features

Reverse-translation of peptide sequences into DNA libraries for high-throughput protein sequencing.

Compatibility with next-generation sequencing (NGS) platforms for scalable analysis.

Affinity reagent binders with DNA barcode tags for amino acid identification.

Ability to create billions of library elements, each identifying an amino acid in the peptide.

Integration with multiomic data analysis pipelines.

Target Audience

The primary target audience includes researchers and scientists in the fields of proteomics, genomics, personalized medicine, and multiomics, as well as pharmaceutical and biotechnology companies.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.